April 26, 2024
A key Japanese health ministry advisory panel will discuss whether to recommend approval for Eli Lilly’s non-covalent BTK inhibitor pirtobrutinib and label expansions for other medicines at its meeting on May 9. Pirtobrutinib, approved overseas as Jaypirca, is the only...read more